Home / Publications
Lisa A. Grohskopf, MD; Leslie Z. Sokolow, MSc, MPH; Sonja J. Olsen, PhD; et al. -- 2015.
Centers for Disease Control and Prevention - Morbidity and Mortality Weekly Report - August 7, 2015. Read More
Arnold Monto, MD; Kristin Nichol, MD, MPH; H. Keipp Talbot, MD, MPH; William Schaffner, MD -- 2011.
People of all ages can become infected with influenza virus, but the infection is particularly serious in older adults. Read More
Haq K, McElhaney JE -- 2014.
Aging is associated with a decline in the normal function of the immune system, both cellular and humoral, which often leads to a state of 'immunosenescence'. Read More
McElhaney JE -- 2011.
The most profound consequences of immune senescence with respect to public health are the increased susceptibility to influenza and loss of efficacy of the current split-virus influenza vaccines in older adults, which are otherwise very effective in younger populations. Read More
Sook-San Wong and Richard J. Webby -- 2013.
The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, and the production and manufacturing limitations to ensure safe, timely, and adequate supply of vaccine. Read More
Osterholm MT, Kelley NS, Manske JM, Ballering KS, Leighton TR, Moore KA -- 2012.
Dating back to Hippocrates, influenza has been and continues to be one of the “lion kings” of infectious diseases. Read More
Lambert LC, Fauci AS -- 2010.
Each year, seasonal epidemics of influenza cause serious illness and death throughout the world. In the United States, the annual burden of disease is estimated to be 25 million to 50 million cases of influenza, resulting in an average of 225,000 hospitalizations. Read More
Chen WH, Kozlovsky BF, Effros RB, et al. -- 2009.
Successful vaccination of the elderly against important infectious pathogens that cause high morbidity and mortality represents a growing public health priority. Read More
DiazGranados CA, Dunning AJ, Kimmel M, et al. -- 2012.
As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 years of age or older. This study evaluated whether IIV3-HD also improves protection against laboratory-confirmed influenza illness. Read More
CAMBRIDGE, Mass., Sept. 15, 2015 /PRNewswire/
NVS Influenza Vaccines, now owned and operated by the CSL Limited, announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted to recommend licensure of a candidate vaccine to help protect against seasonal influenza in those aged 65 years and older via accelerated approval. Read More
DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP -- 2015.
A randomized trial demonstrated that a high-dose inactivated influenza vaccine (IIV-HD) was 24.2% more efficacious than a standard-dose vaccine (IIV-SD) against laboratory-confirmed influenza illness in adults ≥65 years. Read More
Hector S Izurieta, MD; Nicole Thadani, BS; David K Shay, MD; et al. -- 2015.
A high-dose trivalent inactivated influenza vaccine was licensed in 2009 by the US Food and Drug Administration (FDA) on the basis of serological criteria. We sought to establish whether high-dose inactivated influenza vaccine was more effective for prevention of influenza-related visits and hospital admissions in US Medicare beneficiaries than was standard-dose inactivated influenza vaccine. Read More
Keitel WA, Atmar RL, Cate TR, et al. -- 2006.
Immune responses after influenza immunization are reduced in elderly individuals, the group at greatest risk for complications and death after influenza. Improved vaccines are needed to address this problem. Read More
Van Buynder PG1, Konrad S, Van Buynder JL, et al. -- 2013.
Influenza is associated with a high mortality and morbidity in older adults. Vaccination remains the most effective method of preventing influenza and its consequences, however, vaccine effectiveness decreases with increasing age and increasing immunosenescence. Read More
Mannino S, Villa M, Apolone G, et al. -- 2012.
Although vaccination against influenza is recommended for elderly and high-risk patients in many countries, efficacy in the elderly has been suboptimal. Read More
World Health Organization (WHO) -- 2015.
What is the vaccine effectiveness of seasonal influenza vaccines? How is vaccine effectiveness measured? What factors influence the vaccine effectiveness estimate? Read More
Brendan Flannery, PhD, Jessie Clippard, MPH, Richard K. Zimmerman, MD, et al. -- 2015.
In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months. Each season since 2004–05, CDC has estimated the effectiveness of seasonal influenza vaccine in preventing medically attended acute respiratory illness (ARI) associated with laboratory-confirmed influenza. Read More
Plotkin S, Orenstein WA, Offit P. -- 2013.
Find all the details you need to know about vaccinations - a detailed perspective of each disease. Read More